← All stories

Markets 1 sources

Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain

Covered by 1 source · 1 article

Covered by

All coverage

Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain

Yahoo Finance News 1h ago

Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain

More top stories